In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985.

Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008), Nordic Countries (2010) [9] and Netherlands (2013).

In 2012, Almirall opened its first North America subsidiary, based in Canada[9] and launched aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the United States under the brand Tudorza Pressair.

The company launched linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C) and opened its Netherlands subsidiary.

The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities.

The company also has three production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 13 affiliates in Germany, Austria, Belgium-Luxembourg, the United States, France, the Netherlands, Italy, the Nordic countries, Poland, Portugal, the United Kingdom-Ireland, Spain, and Switzerland.